Proteases as tools for diagnosis and novel therapeutics

S. Meiners (München, Germany)

Source: ERS Research Seminar 2015
Number: 5

PDF journal article, handout or slidesSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Meiners (München, Germany). Proteases as tools for diagnosis and novel therapeutics. ERS Research Seminar 2015

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Novel targets and emerging therapies in MPM
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019

Novel therapeutics for CF
Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission
Year: 2019

From anti-PD1/L1 inhibitors to new immunotherapies
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019

Clinical implications and novel therapies
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018

Novel NTM treatments and approaches, repurposed to bacteriophages
Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment
Year: 2021

Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020
Year: 2020

Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008

COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007

COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020
Year: 2020

Classic and Novel Adipokines as diagnostic biomarkers in NSCLC
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019

Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use
Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia
Year: 2004

Bronchiectasis: state-of-the-art diagnostic and therapeutic approaches
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021

Genetic studies as a tool for identifying novel potential targets for treatment of COPD
Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Year: 2017

Targeting the arginase pathway: potential developments as new avenues for treatment
Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma?
Year: 2004

The genetics of asthma and the promise of genomics-guided drug discovery
Source: Virtual Congress 2020 – Reducing the burden of asthma
Year: 2020

COPD – will new insights into molecular pathology define new therapies?
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014

Potential of regulatory T-cell-based therapies in the management of severe COVID-19
Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020
Year: 2020